Semax Nasal Spray: What It Is, Where to Get It Prescribed, and What It Costs

Semax is a heptapeptide, sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues are positions 4 to 7 of adrenocorticotropic hormone (ACTH), the pituitary hormone that drives cortisol production; the closing Pro-Gly-Pro was added to slow enzymatic breakdown. That region of ACTH had been studied for decades in animals for effects on attention and learning separate from the hormone's endocrine job. The FDA's 2026 briefing describes Semax as the Russian literature does: an ACTH(4–10) analogue "devoid of the hormonal corticotropic and melanotropic properties" of the parent. It is not expected to raise cortisol, and it is not a steroid, an anabolic agent or a stimulant. The spray is the same molecule as the Semax injection, at a different concentration and by a different route.

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is a registered medicine in Russia, supplied as 0.1% and 1% nasal drops. Every human study of it used the nose; the FDA's 2026 review put it plainly: the only route of administration discussed in the literature was intranasal. So the spray is not a needle-free convenience version of the injection; it is the format the compound was studied in, and the injection is the one with no route-matched human data.

It is not a stimulant and not a substitute for prescribed ADHD treatment; the FDA looked for ADHD literature and found only a 2007 hypothesis paper. It is not a stroke treatment in the United States, and nothing here is a reason to delay emergency care. And it is not an anxiolytic; that is the territory of Selank Nasal Spray, a different peptide from the same programme.

The nasal lining carries olfactory and trigeminal nerve endings that reach the brain without crossing the blood–brain barrier. A 2006 study in Bioorganic Chemistry (Bioorganicheskaya Khimiya) gave rats a tritium-labelled intranasal dose and detected Semax in the brain two minutes later, about 80% still intact, followed by rapid breakdown to the tripeptide Pro-Gly-Pro. A 2010 paper in the Russian Journal of Physiology (Sechenov) compared routes: intranasal Semax was more potent than intraperitoneal injection at improving passive-avoidance learning, while the analgesic effect seen after injection did not appear intranasally. No human pharmacokinetic study exists for any route.

The most cited mechanism. A 2006 paper in Brain Research reported that Semax increased BDNF protein and TrkB receptor phosphorylation in the rat hippocampus, with treated animals showing more conditioned avoidance responses. BDNF is the growth factor most tightly linked to synaptic plasticity, which is what the "cognitive" category rests on.

A 2010 paper in Cellular and Molecular Neurobiology reported that in rats with a middle cerebral artery occlusion, Semax raised transcription of BDNF, NGF and their receptors selectively in ischaemic cortex. A 2014 genome-wide study in BMC Genomics found the largest effect was on immune-response genes, and a 1999 study in stroke patients from the Korsakov Journal reported a shift toward anti-inflammatory mediators; the 2014 authors proposed immune modulation and vascular support as the core of the ischaemia effect.

Animal work describes Semax increasing serotonergic activity; its analgesic effect in rodents was blocked by the serotonin antagonist cyproheptadine, not by naloxone. A mouse study reported Semax potentiating amphetamine-induced dopamine release in the striatum, which the FDA's reviewers flagged as a reason for caution; no human signal of that kind has been reported.

A 2024 paper in the European Journal of Pharmacology reported that in male rats under chronic unpredictable stress, daily low-dose Semax counteracted the loss of sucrose preference, adrenal enlargement and the fall in hippocampal BDNF. A less-discussed strand, summarised in the FDA's review, reports that intranasal Semax in rats increased plasma anticoagulant and fibrinolytic activity.

The indication Semax was built for and the largest body of human work, all intranasal. A 1997 controlled study in the Korsakov Journal of Neurology and Psychiatry compared 30 acute stroke patients given intranasal Semax with 80 matched controls and reported faster regression of deficits, particularly motor. A 2018 trial from the same group followed 110 post-stroke patients with and without Semax; plasma BDNF rose in the Semax subgroups, with faster improvement and higher final Barthel Index scores reported.

A 2005 comparative study, also in the Korsakov Journal, examined 187 patients with chronic cerebrovascular insufficiency and reported clinical improvement, fewer strokes and transient ischaemic attacks during follow-up, and good tolerability. It was not randomised.

A 2000 controlled study in Vestnik Oftalmologii compared patients with vascular, toxic, inflammatory and atrophic optic nerve conditions given intranasal Semax against controls, reporting better acuity, visual field and electrophysiological measures; a 2001 paper reported similar findings in glaucomatous optic neuropathy. Both are small, unblinded series.

A 2018 paper in the Bulletin of Experimental Biology and Medicine gave 14 healthy adults a single intranasal dose and measured changes in the brain's default mode network on functional MRI. There is no published randomised trial of intranasal Semax for attention, memory or productivity in healthy people.

A 1996 open-label study gave a single intranasal dose to adults with migraine or facial pain. Some migraine patients reported their headache resolving within two hours; the trigeminal neuralgia patients showed no change. The FDA's 2026 review concluded the study did not support effectiveness for either condition.

There are no randomised, placebo-controlled trials of Semax published in English-language, peer-reviewed journals. What exists is a body of Russian clinical studies — some controlled, most open-label, several over a hundred patients — in stroke, chronic cerebrovascular disease and optic nerve disease, every one using the intranasal product. The FDA excluded them from its 2026 review not on quality grounds but because complete English translations were not supplied, as its regulations require; on what it could read, it found insufficient evidence of effectiveness.

The honest framing: the spray is the route the human evidence used; that evidence is Russian, mostly unblinded, and in neurological patients rather than healthy adults. Any source describing Semax as "clinically proven" is overstating it, spray or injection.

• It does not establish an effect on memory, focus or attention in healthy adults. No trial has measured that.
• It does not establish human pharmacokinetics by any route; the absorption work is in rats.
• It does not establish long-term safety over years of continuous use.
• It does not establish efficacy for any condition as an FDA-approved treatment. It is not approved for anything in the United States.

Most people report nothing dramatic. Some describe a short window of alertness in the hour after a dose, which fits the rat pharmacokinetics and is not evidence of anything lasting.

If there is an effect on mood or sustained attention it is usually described in this window, as a background change rather than an event — easier to start tasks, less mental fatigue late in the day — which is easy to overattribute. A simple daily log is more useful than memory.

The peptide is cleared quickly — the rat work shows most of a dose metabolised within hours — and the Russian product is labelled for several administrations a day for the same reason. A second dose late in the evening is the usual cause of restlessness at night.

There is no withdrawal or rebound described in the literature. Whether anything persists is unknown; the Russian follow-up data is in brain-injured patients, not healthy adults. Whether to continue is decided with your physician at review.

One spray into each nostril is 0.2 mL in total, which at 2.5 mg/mL is 0.5 mg of Semax per dose, or 1 mg a day at twice daily. The pump meters the volume and the number is printed on your medication. The registered Russian drops come as 0.1% and 1%; the compounded spray sits between them and is not the registered product. There is one strength, and the schedule and any change to it are your physician's decision.

Blow your nose first if it is congested. Sit upright, tilt the head slightly forward, close one nostril and spray into the other while breathing in gently — not sniffing hard, which pulls the dose down the throat. Repeat on the other side. A cold or heavy allergies make absorption less predictable; tell your physician if that lasts.

The bottle holds 100 metered doses. Refills run on Pepti's 28-day cycle, one bottle per fill — not a stockpile — and your physician reviews before each refill.

Refrigerated, and it ships that way in insulated packaging with ice packs. Keep it in the fridge between doses and wipe the nozzle after use. Beyond-use dating runs from first use and is on the label.

Same molecule, different route, and for once the evidence tilts toward the needle-free option. The Semax injection delivers a precise syringe-measured volume and is available in all 50 states and DC. The spray is the route every human study used; the FDA's 2026 review found no safety data for subcutaneous Semax, and in rats the intranasal route was at least as effective on learning measures. Against that, the spray depends on a metered pump and the state of your nasal lining, and it ships to 23 states. Which you are prescribed is your physician's decision.

Same institute, same format, different parents. Semax is built from ACTH(4–7) and is described around BDNF and attention; Selank Nasal Spray is built from the immune peptide tuftsin and is described around GABAergic tone and anxiety. In practice Semax is the one for focus, Selank for stress and rumination.

Where both peptides are wanted, Pepti supplies a combined Semax + Selank injection — one vial rather than two bottles. That is a trade between the studied route and the convenience of one preparation, and a physician may reasonably prefer either.